Antibodies against cdcp1 for the treatment and detection of cancer
AssigneeThe Regents of the University of California
InventorsJames A. WELLS, Alexander J. MARTINKO, Juan E. DIAZ, Michael J. HORNSBY
Life of this patent
Estimating the term…
Abstract
The disclosure is related to antibodies and antibody fragments that specifically bind the CUB domain-containing protein 1 (CDCP1) and their methods and uses in treating and detecting cancers.
Claims14
1-22. (canceled)
A method for assessing CUB domain-containing protein 1 (CDCP1) expression, comprising:
- (a) administering a radioisotope-labeled antibody or antibody fragment that specifically binds the CDCP1 ectodomain to a subject having pancreatic cancer;
- and
- (b) visualizing binding of the antibody or antibody fragment to cells of the subject to assess CDC1 expression, wherein
- the radioisotope is a positron-emitter, and
- the antibody or antibody fragment comprises light chain CDRs of SEQ ID NO:11, SEQ ID NO:13 and SEQ ID NO:20, and heavy chain CDRs of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19.
A radioisotope-labeled antibody or antibody fragment that specifically binds CUB domain-containing protein 1 (CDCP1) ectodomain and comprises light chain CDRs of SEQ ID NO:11, SEQ ID NO:13 and SEQ ID NO:20, and heavy chain CDRs of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19, wherein the radioisotope is a positron-emitter.
Dependencies are inferred from the claim text.